Correction for Underwood et al., "Integrase Inhibitor Resistance Mechanisms and Structural Characteristics in Antiretroviral Therapy-Experienced, Integrase Inhibitor-Naive Adults with HIV-1 Infection Treated with Dolutegravir plus Two Nucleoside Reverse Transcriptase Inhibitors in the DAWNING Study".

Underwood, Mark; Horton, Joe; Nangle, Keith; Hopking, Judy; Smith, Kimberly; Aboud, Michael; Wynne, Brian; Sievers, Jörg; Stewart, Eugene L; Wang, Ruolan

Underwood, Mark; Horton, Joe; Nangle, Keith; Hopking, Judy; Smith, Kimberly; Aboud, Michael; Wynne, Brian; Sievers, Jörg; Stewart, Eugene L; Wang, Ruolan.

Afiliação

Underwood M; ViiV Healthcare, Research Triangle Park, North Carolina, USA.
Horton J; Parexel International, Durham, North Carolina, USA.
Nangle K; Parexel International, Durham, North Carolina, USA.
Hopking J; GlaxoSmithKline, Stockley Park, United Kingdom.
Smith K; ViiV Healthcare, Research Triangle Park, North Carolina, USA.
Aboud M; ViiV Healthcare, Brentford, United Kingdom.
Wynne B; ViiV Healthcare, Research Triangle Park, North Carolina, USA.
Sievers J; ViiV Healthcare, Brentford, United Kingdom.
Stewart EL; GlaxoSmithKline, Upper Providence, Pennsylvania, USA.
Wang R; ViiV Healthcare, Research Triangle Park, North Carolina, USA.

Antimicrob Agents Chemother ; 67(3): e0032622, 2023 Mar 16.

Article em En | MEDLINE | ID: mdl-36794938

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2023 Tipo de documento: Article